Search Results
Your search for Sandra M. Swain, MD matches 93 pages
Showing 1 - 50Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past dozen years, many in the oncology community have been profiled in this special issue. A complete list of individuals...
Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past years, many in the oncology community have been profiled in this commemorative issue. A complete list of individuals...
Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past years, many in the oncology community have been profiled in this commemorative issue. Here is a complete list of...
Narratives in Oncology Through the Years
Beginning in 2012,The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past years, many in the oncology community have been profiled in this commemorative issue. A complete list of individuals...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer (WWCC) is a groundbreaking program that is committed to supporting early-career women researchers by funding research grants through Conquer Cancer, the ASCO Foundation®. Since its inception 7 years ago, the program has raised nearly $5 million, funded 27 Young Investigator ...
The ASCO Post and Narratives in Oncology Through the Years
THE ASCO POST is pleased to acknowledge its 10th anniversary. Our first issue was launched in June 2010 at the ASCO Annual Meeting. Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling leaders in the oncology community. To nominate an...
Pooled Analysis Supports Benefit of Dual HER2-Targeted Therapy, but Questions Remain
In the treatment of HER2-positive early breast cancer, patients who receive dual HER2-targeted therapy in both the neoadjuvant and adjuvant settings are less likely to experience recurrence than those who received dual therapy only as neoadjuvant treatment, according to a pooled analysis of...
End-of-Study Results From CLEOPATRA: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
As reported in The Lancet Oncology by Sandra M. Swain, MD, and colleagues, long-term follow-up of the phase III CLEOPATRA trial has shown maintained overall survival benefit with the addition of pertuzumab to trastuzumab plus docetaxel in patients with previously untreated HER2-positive metastatic...
Former ASCO President Sandra M. Swain, MD, FACP, FASCO, Shares Highlights of a Noted Career
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Sandra M. Swain, MD, FACP, FASCO, Professor of Medicine and Associate Dean for Research Development at Georgetown University Medical Center, and Vice President of MedStar Genetic Medicine at Medstar...
Taking Action Against Cancer: Celebrating 20 Years of World Cancer Day
February 4, 2020, will mark the 20th anniversary of World Cancer Day, an annual event meant to raise cancer awareness and encourage governments, oncology societies, nongovernmental organizations, businesses, and individuals to take action against the global impact of the disease. Formed in...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer (WWCC) is a groundbreaking program that is committed to supporting early-career women researchers by funding research grants through Conquer Cancer®, the ASCO Foundation. Since its inception 6 years ago, the program has raised over $4 million, funded 21 Young Investigator...
ASCO Presidents Through the Years: Past, Present, and Future
2020–2021: Lori J. Pierce, MD, FASTRO 2019–2020: Howard “Skip” Burris, III, MD, FACP 2018–2019: Monica M. Bertagnolli, MD 2017–2018: Bruce E. Johnson, MD 2016–2017: Daniel F. Hayes, MD 2015–2016: Julie Vose, MD, MBA 2014–2015: Peter P. Yu, MD 2013–2014: Clifford A. Hudis, MD 2012–2013: Sandra M....
Special Events at the 2019 ASCO Annual Meeting
1. (Left to right) Sandra Swain, MD, FASCO, Lynn M. Schuchter, MD, FASCO, and Linda Bosserman, MD, FACP, FASCO, among the speakers and guests at the Women Leaders in Oncology Event, held in conjunction with the ASCO Annual Meeting, June 3, 2019. Photo by © ASCO/Matt Herp 2019. 2. Attendees at the...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer (WWCC) is a groundbreaking program that is committed to supporting early-career female researchers by funding research grants through Conquer Cancer, the ASCO Foundation. Since its inception 6 years ago, the program has raised over $4 million, has funded 21 Young...
Spotlight on Women Who Conquer Cancer
WOMEN WHO CONQUER CANCER (WWCC) is a groundbreaking program that is committed to supporting early-career female researchers by funding research grants through Conquer Cancer, the ASCO Foundation. Since its inception 6 years ago, the program has raised over $4 million, funded 21 Young Investigator...
Expert Point of View: Eric P. Winer, MD, FASCO, and Sandra M. Swain, MD, FACP, FASCO
Eric P. Winer, MD, FASCO, Thompson Chair in Breast Cancer Research and Professor of Medicine, Harvard Medical School, and Director of the Breast Cancer Program at Dana-Farber Cancer Institute, Boston, commented on Dr. Sparano’s presentation for The ASCO Post. “We already use information in...
CLEOPATRA End-of-Study Analysis in Metastatic Breast Cancer: 37% Alive at 8 Years
The end-of-study analysis of the landmark CLEOPATRA trial shows that 37% of patients with HER2-positive metastatic breast cancer are still alive at 8 years, according to principal investigator Sandra M. Swain, MD, FACP, FASCO, Associate Dean for Research Development at Georgetown University Medical ...
ASCO Through the Years: Past Presidents
Over the years many great oncology leaders have served at the helm as ASCO President. We recognize these individuals here, and extend our gratitude for their service and efforts to champion high-quality cancer care. 2018-2019: Monica M. Bertagnolli, MD 2017-2018: Bruce E. Johnson, MD 2016-2017:...
ASCO Kicks Off Strategic Planning to Support Women in Oncology
Women in oncology aren’t ascending the leadership ladder at rates anywhere close to their male counterparts—and ASCO wants to fix that. The most recent report on “The State of Women in Academic Medicine” from the Association of American Medical Colleges (AAMC) said that although women make up...
Highlights From the Conquer Cancer Foundation’s Third Annual Career Development Retreat
The Conquer Cancer Foundation of ASCO is committed to supporting the research and career development of young researchers through its Grants & Awards Program. In October 2017, Conquer Cancer hosted its third Scientific and Career Development Retreat at ASCO Headquarters in Alexandria,...
ASCO Presidents Through the Years
2016–2017 Daniel Hayes, MD 2015–2016 Julie Vose, MD, MBA 2014–2015 Peter Paul Yu, MD, FACP 2013–2014 Clifford A. Hudis, MD, FACP 2012–2013 Sandra M. Swain, MD 2011–2012 Michael P. Link, MD 2010–2011 George W. Sledge, Jr, MD 2009–2010 Douglas W. Blayney, MD 2008–2009 Richard...
Forging a New Role to Make Curing More Cancers a Reality
For more than 3 decades, Nancy E. Davidson, MD, has dedicated her clinical and research career to better understanding the molecular mechanisms driving the development of breast cancer and to the discovery of more effective therapies to treat the disease. The recipient of an ASCO Young...
Conquer Cancer Foundation Hosts Successful Scientific and Career Development Retreat
In October 2016, the Conquer Cancer Foundation of ASCO (CCF) hosted its Second Scientific and Career Development Retreat at ASCO headquarters in Alexandria, Virginia. Attendees included Career Development Award (CDA) and Young Investigator Award (YIA) recipients awarded between 2010 and 2016; ASCO ...
Women in Oncology: Breaking Down Barriers and Looking to the Future
There has been no better time than the present for women in the field of oncology: Women at all stages of their careers are finding more opportunities and avenues to excel. At the time of the last ASCO workforce survey, women made up 28.4% of the oncologist workforce, and that proportion is rising...
Sarah S. Donaldson, MD, FASCO, Honored With Inaugural Women Who Conquer Cancer Mentorship Award
Sarah S. Donaldson, MD, FASCO, of Stanford University School of Medicine and Lucile Packard Children’s Hospital, is the recipient of the Inaugural Women Who Conquer Cancer Mentorship Award. Throughout her decades-long career, Dr. Donaldson has mentored countless trainees and young oncologists,...
Women’s Networking Center Addresses Gender Gap, Provides Mentorship for Annual Meeting Attendees
ASCO is committed to providing all oncologists with opportunities for professional development that will maximize their career success. In response to the recognized career gender gap for women in oncology, ASCO included a number of initiatives in the 2016 Annual Meeting program. In its 2nd year,...
Global Cancer: The Current Reality and the Future Need for Action
The estimated number of cancer cases worldwide in 2008 was 12.7 million, with 7.6 million deaths. By 2030, it is estimated that there will be 22 million newly diagnosed cancer cases and 12 million deaths, shocking to contemplate in dollars and human suffering. Although this impending disaster has...
CCF Names Thomas G. Roberts, Jr, MD, New Board of Directors Chair, Appoints Two New Leaders
Thomas G. Roberts, Jr, MD, a global investor and oncologist, has been named as the new Chair of the Conquer Cancer Foundation (CCF) Board of Directors. Two new members of the Board have also been announced: Margaret Tempero, MD, FASCO, a Past President of ASCO and a pioneer in cancer treatment and...
Newly Elected Society Officials for 2011
In December 2010, ASCO announced the results of its 2011 Election for President-Elect and for members of the Board of Directors and the Nominating Committee. Sandra M. Swain, MD (Washington Hospital Center’s Washington Cancer Institute, Georgetown University, and Uniformed Services University of...
New ASCO President Reflects on Value of Mentorship and Addressing Health-care Disparities
Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at the MedStar Washington Hospital Center in Washington, DC, and ASCO President for the 2012 to 2013 term, is a leading authority on breast cancer treatment with a global reputation in cutting-edge clinical research. The...
Special Anniversary Issue: Narratives in Oncology
The ASCO Post is pleased to present this special anniversary edition in recognition of the publication's 3rd year serving the oncology community. We hope you enjoy this special commemorative issue profiling several of the many leaders in the oncology community. In coming issues ofThe ASCO Post and...
ASCO’s CancerLinQ: Building a Transformation in Cancer Care
Cancer science and information technology are advancing rapidly, but the way we care for patients today cannot fully capitalize on those advances. The proliferation of scientific results and novel treatments is a growing challenge for all oncology professionals as we enter the era of highly...
Older Chemotherapy Studies in Breast Cancer Coming of Age
Results of several long-running chemotherapy trials were reported at the 2012 ASCO Annual Meeting breast cancer oral session, reported in brief here. NSABP B-38 The final analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-38 trial showed that the addition of gemcitabine...
ASCO Responds to Supreme Court Ruling on Health-care Law
When the Supreme Court upheld the Patient Protection and Affordable Care Act on June 28, ASCO released a statement by ASCO President Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center. Critically Important Provisions In the statement, Dr....
All Oncology Care Practices Urged to ‘Be Counted’ in Groundbreaking Census
The National Oncology Census, sponsored by the American Society of Clinical Oncology (ASCO), represents the first-ever attempt to capture comprehensive, real-time data on the state of oncology practice in the United States. ASCO is urging all U.S. oncology practices—representing oncologists in...
Biomedical Research Faces Imminent $2.4 Billion Budget Cut Unless Congress Acts
The National Institutes of Health (NIH) faces a significant budget reduction in January 2013 due to automatic across-the-board cuts, known as sequestration, required under the federal Budget Control Act of 2011. The estimated $2.4 billion NIH cut could result in 700 to 2,300 fewer research grants...
SIDEBAR: Cardiac Events Evaluated in Trastuzumab Studies
The effect of duration on cardiac events was a key question for the PHARE and HERA trials to answer. In general, longer duration of treatment was associated with more cardiac events, especially declines in left-ventricular function, but overall the risks were low. Cardiac Endpoints In the PHARE...
Expert Point of View: Sandra M. Swain, MD
Commenting on the PHARE trial and HERA update presented at ESMO, ASCO President Sandra M. Swain, MD, of Washington Hospital Center’s Washington Cancer Institute, said “Today we have seen that 12 months of trastuzumab is better than 6 months, and 12 months is the same as 2 years of treatment, so...
Richard L. Schilsky, MD, Chosen to Serve in New ASCO Leadership Position, Chief Medical Officer
Richard L. Schilsky, MD, Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center, has been named to the newly created position of Chief Medical Officer (CMO) of ASCO. A former ASCO President and Fellow of the American...
ASCO Calls on Congress to Avoid Looming ‘Fiscal Cliff’
As Congress reconvenes for its lame duck session, ASCO calls on lawmakers to prevent devastating budget cuts to cancer care, research, and the drug review process citing the negative impact to millions of individuals who have cancer. The mandated cuts, known as “sequestration” under the Budget...
Shaping the Future of Oncology: Envisioning Cancer Care in 2030
Over the course of the last year, the ASCO Board of Directors worked to identify “drivers of change” that will have the greatest impact on the oncology field over the next two decades. “We are on the verge of a new age of cancer care, in which emerging scientific, technical, and economic trends are ...
Expert Point of View: Peter Ravdin, MD and Sandra M. Swain, MD, FACP
Putting these results in perspective, Peter Ravdin, MD, moderator of a San Antonio Breast Cancer Symposium press conference where ATLAS findings were discussed, said that in the United States, there is currently a different strategy for pre- and postmenopausal women. Tamoxifen is used as primary...
Expert Point of View: Sandra M. Swain, MD, FACP, and Lisa Carey, MD
Sandra M. Swain, MD, FACP, Medical Director, Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, who moderated the session, said these interesting observations must now be validated in preclinical models of triple-negative tumors, and then tested in patients. “Residual...
Expert Point of View: Sandra M. Swain, MD, FACP and Eric P. Winer, MD
Commenting on the study presented by Dr. Wolff at the 2012 San Antonio Breast Cancer Symposium, ASCO President Sandra M. Swain, MD, FACP, Medical Director, Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, said she found it “disturbing” that about half the population...
Sequestration Will Have Shattering Impact on Entire U.S. Cancer Enterprise
March 1 marked the beginning of sequestration, the unprecedented automatic budget cuts that immediately take effect across the federal government—after months of futile negotiations by the President and Congress. Sequestration will have a shattering impact on the entire cancer enterprise in the...
ASCO International Expands to Improve Cancer Care Worldwide
As a global community of cancer care providers in more than 100 countries around the world, ASCO is uniquely positioned to improve cancer patient outcomes worldwide—an opportunity that it has seized since the organization’s inception through numerous innovative programs. Building upon this...
New Partnership Will Harness Technology to Foster Improved Palliative Care in Oncology
ASCO and the American Academy of Hospice and Palliative Care Medicine (AAHPM) have announced a joint initiative to support delivery of high-quality palliative care in medical oncology. The initiative, funded by the Agency for Health Care Research & Quality, aims to address the complex care...
Increase in Advanced Breast Cancer among Younger Women Is Small but Significant, and Trend Is Likely to Continue
The incidence of advanced breast cancer among women aged 25 to 39 years increased by an average of 2.07% per year from 1976 to 2009 and the trend seems likely to continue, according to an analysis of data for 936,497 women diagnosed with malignant breast cancer. The small but statistically...
New ASCO/AAHPM Project Will Harness Technology to Foster Improved Palliative Care in Oncology
ASCO and the American Academy of Hospice and Palliative Care Medicine (AAHPM) recently announced a joint initiative to support delivery of high-quality palliative care in medical oncology. The initiative is funded by ASCO’s first-ever grant from the Agency for Health Care Research Quality. The...
CancerLinQ Prototype Demonstrates Use of Big Data in Clinical Care
ASCO has unveiled the prototype of a computer system that will allow oncologists, from their desks, to leverage “big data” to measure the quality of care that their practices provide. The prototype is a major step in the development of CancerLinQ, a system that will eventually allow millions of...
